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ABSTRACT
Introduction Delirium is a severe neuropsychiatric 
syndrome of rapid onset, commonly precipitated by acute 
illness. It is common in older people in the emergency 
department (ED) and acute hospital, but greatly under-
recognised in these and other settings. Delirium and other 
forms of cognitive impairment, particularly dementia, 
commonly coexist. There is a need for a rapid delirium 
screening tool that can be administered by a range of 
professional-level healthcare staff to patients with sensory 
or functional impairments in a busy clinical environment, 
which also incorporates general cognitive assessment. 
We developed the 4 'A's Test (4AT) for this purpose. This 
study’s primary objective is to validate the 4AT against 
a reference standard. Secondary objectives include (1) 
comparing the 4AT with another widely used test (the 
Confusion Assessment Method (CAM)); (2) determining if 
the 4AT is sensitive to general cognitive impairment; (3) 
assessing if 4AT scores predict outcomes, including (4) a 
health economic analysis.
Methods and analysis 900 patients aged 70 or over 
in EDs or acute general medical wards will be recruited 
in three sites (Edinburgh, Bradford and Shefield) over 
18 months. Each patient will undergo a reference 
standard delirium assessment and will be randomised 
to assessment with either the 4AT or the CAM. At 12 
weeks, outcomes (length of stay, institutionalisation and 
mortality) and resource utilisation will be collected by a 
questionnaire and via the electronic patient record.
Ethics and dissemination Ethical approval was granted 
in Scotland and England. The study involves administering 
tests commonly used in clinical practice. The main ethical 
issues are the essential recruitment of people without 
capacity. Dissemination is planned via publication in high 
impact journals, presentation at conferences, social media 
and the website www. the4AT. com.
Trial registration number ISRCTN53388093; Pre-results.
InTRoduCTIon
Background
Delirium is a severe and distressing neuropsy-
chiatric syndrome which is characterised by 
acute deterioration in attention and other 
mental functions. The diagnostic criteria 
are, in summary: a disturbance of conscious-
ness (ie, reduced ability to focus, sustain or 
shift attention) and a change in cognition. 
The mental status deterioration develops 
over short periods of time (usually hours to 
days) and it tends to fluctuate.1 2 Delirium 
is commonly precipitated by acute illness, 
trauma or the side effects of medications. The 
presence of a ‘medical condition’ is part of the 
Diagnostic and Statistical Manual for Mental 
Disorders, fourth and fifth Edition (DSM-
IV, DSM-5) criteria. Delirium is extremely 
common: it affects at least 15% of patients in 
acute hospitals and is more common in older 
people.3–5 It is independently associated with 
many poor outcomes.6–10 Delirium is also a 
marker of current dementia6 11 and is associ-
ated with acceleration of existing dementia.12 
In older patients without dementia, an 
episode of delirium strongly predicts future 
dementia risk.7 13 The economic burden of 
Strengths and limitations of this study
 Ź The study protocol involved seeking a representative 
sample of older acute medical patients in the 
emergency department and acute medical wards. A 
detailed, structured reference standard with explicit 
and reproducible methods is used to assess the 
features of delirium and reach a diagnosis.
 Ź Two different rating scales, the 4 ‘A’s Test (4AT) 
and the Confusion Assessment Method are being 
evaluated in similar groups of patients.
 Ź Reference standard and index assessments were 
performed blinded to each other.
 Ź A limitation of the study is that participants or legal 
proxies were required to give consent and thus the 
sample was selected.
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delirium derived from 2008 US data estimates the 1-year 
healthcare costs to be $38–$152 billion,13 but there are 
limited recent data on the costs associated with delirium.
Detection of delirium is essential because it indicates 
acute systemic or central nervous system illness, physio-
logical disturbance and drug intoxication or withdrawal. 
Failure to detect delirium in the acute setting is associ-
ated with worse outcomes.14 Specific management of 
delirium is of obvious and immediate benefit to patients 
in many clinical situations, for example, in reversing 
opioid toxicity, treatment of peripheral infections which 
have presented with delirium, alleviating distress caused 
by delusions and hallucinations15 and in prompting more 
thorough assessment of symptoms.16
More broadly, detecting cognitive impairment in 
general (delirium, dementia, depression, learning 
disability, etc) is a prerequisite for high-quality care 
because of the multiple immediate implications of 
cognitive impairment for patients and staff, including: 
ensuring adequate communication with patients and 
their families, doing careful assessment of capacity to 
provide consent for clinical procedures, avoiding giving 
treatments contrary to the law because of lack of consent, 
alleviating distress more readily, avoiding unnecessary bed 
transfers and prompting delirium prevention, including a 
detailed drugs review. Detection of dementia has recently 
been highlighted in the Dementia Commissioning for 
Quality and Innovation framework in operation in NHS 
England.17
In general medical and emergency department 
(ED) settings, delirium is grossly underdetected: at least 
two-thirds of cases are missed.5 18 19 It is unclear why detec-
tion rates are so low. Evidence from surveys and work-
shops has raised several possibilities, including general 
ignorance about delirium, lack of awareness of its impor-
tance, uncertainty about discriminating delirium from 
dementia and lack of time for assessment in the acute 
setting.20–24 The lack of a very rapid, simple and validated 
screening tool is a major factor in the underdetection of 
delirium.
Many delirium assessment instruments have been 
developed that operationalise the standard diagnostic 
criteria for delirium, but these have largely remained 
research tools. The most commonly advocated screening 
tool for use in routine clinical care, the short Confusion 
Assessment Method (CAM),25 has satisfactory sensitivity 
and specificity in trained hands though takes around 
10 min to complete because it requires a cognitive assess-
ment like the Modified Mini-Cog26 27 to be done first. The 
CAM also requires the rater to make subjective judge-
ments of mental status. Subjective judgements are less 
reliable, often more time-consuming and more difficult 
for staff (particularly non-specialists) than simple objec-
tive measures with clearly defined cut points.27
The problem of some patients being ‘untestable’ is 
likely to be another important factor in delirium under-
detection: many patients in acute settings are too unwell, 
sleepy or agitated to undergo cognitive testing or even 
interview.28–31 Most screening tools do not make explicit 
how these patients should be classified. The result is that 
mental status assessments are often simply left uncom-
pleted in most ‘untestable’ patients, and no diagnosis, 
and often no specific treatment, is applied. This lack of 
diagnosis can be harmful.14
Finally, given the time pressures in acute settings, it is 
challenging to implement a separate delirium screening 
instrument in addition to any existing general cognitive 
screening instruments. The lack of a combined instru-
ment allowing screening for both general cognitive 
impairment and delirium may therefore contribute to 
the lack of specific delirium detection. Early diagnosis 
of delirium using evidence-based diagnostic tools offers 
a means for improved outcomes and more efficient 
resource allocation decisions.
Rationale for the study
Given the multiple constraints of the acute environment, 
the range of staff that might be expected to screen for 
delirium, the common coexistence of delirium and 
dementia and the heterogeneity of patients, we deter-
mined the requirements for a screening tool (box 1).
There are multiple instruments for delirium 
screening, diagnosis, severity assessment and moni-
toring.32–35 Before deciding to design a new screening 
tool, we therefore examined each of the available 
tools against the above criteria, focusing on screening 
tools such as the CAM. We also searched the litera-
ture systematically, including conference proceedings, 
books and book chapters, for any newly published tools 
as well as to examine the study data for each tool. Most 
scales were excluded on grounds of duration alone. 
The remaining scales lacked features such as general 
cognitive screening and other important features. We 
thus found that, in late 2010, no existing tool fulfilled 
the above requirements, and because of this we decided 
to design a new test. This conclusion was supported by 
Box 1 Requirements for a screening tool for delirium for 
use in the acute hospital environment
 Ź Short (less than 2 min)
 Ź Easy to learn
 Ź Easy to administer and score
 Ź Can be used by professional-level healthcare staff from a variety of 
disciplines
 Ź Allows scoring of patients who are too drowsy or agitated to undergo 
cognitive testing or clinical interview
 Ź Takes account of informant history
 Ź Can be administered through written questions to people with 
severe hearing impairment
 Ź Can be administered to patients with visual impairments
 Ź Does not require subjective judgements based on interview
 Ź Combines delirium screening with general cognitive screening
 Ź Does not need a quiet environment for administration
 Ź Does not require physical responses such as drawing igures or 
clocks
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the National Institute for Health and Care Excellence 
(NICE) Guidelines on Delirium6 which emphasised the 
need for research on a screening tool for delirium suit-
able for routine use.
The subsequent design process involved scrutiny of 
each of the nearly 30 published delirium assessment tools, 
evaluating the performance of each, including subtests, 
in published studies and, in most cases, through direct 
clinical or research experience of their use. Because we 
had decided to incorporate general cognitive screening 
into the new instrument, to avoid the need to have sepa-
rate instruments for cognitive screening and delirium 
screening, we also reviewed the broader literature on 
brief tests for general cognitive impairment (including 
dementia). In the context of designing a screening tool 
for the acute hospital, it is important to note that delirium 
generally causes cognitive impairment detectable on the 
kinds of tests used for dementia screening.36 37 There-
fore, abnormal test results may indicate delirium and/
or dementia (as well as other causes of cognitive impair-
ment, such as learning disability).
It is clinically essential to know if any such impairment 
is acute, that is, delirium, but also important to identify 
underlying general (acute or chronic) cognitive impair-
ment. A tool designed exclusively to detect cognitive 
impairment will not lead to delirium detection without 
another step, and a tool designed only to detect delirium 
may miss general cognitive impairment. In this light, we 
decided that the 4 'A's Test (4AT) should include cogni-
tive screening sensitive to general cognitive impairment, 
but also including items on altered level of alertness and 
change in mental status, both of which are strong indica-
tors of delirium.
The first version of the 4AT was drafted and tested infor-
mally by colleagues, changes were made based on feed-
back and updated versions were tested again. After several 
iterations involving 20 doctors and nurses of varying levels 
of experience, the final version was produced. An initial 
audit in 30 inpatients comparing clinical use of 4AT with 
independent reference standard DSM-IV assessment 
found 100% sensitivity (CI 69% to 100%) and 90% spec-
ificity (CI 68% to 99%). A subsequent validation study in 
Italy involving 234 consecutively recruited older hospital-
ised patients found that the 4AT had a sensitivity of 89.7% 
and a specificity of 84.1% for delirium.38 The area under 
the receiver operating characteristic (ROC) curves for 
delirium diagnosis was 0.93. Since the 4AT was launched, 
locally and through the www. the4AT. com website, it has 
been adopted in clinical units in several centres in the UK 
and internationally.
Thus, in 2014, there was encouraging evidence that 
the 4AT has value as a tool for delirium detection in 
routine practice. This evidence came from several 
sources: one published study, audits in several sites, 
informal feedback, adoption in clinical practice by 
several clinical units globally and a recent web-based 
survey focused specifically on 4AT provided evidence 
supporting its use. Since this study was designed, other 
validation studies have been published, with favourable 
results; however, these included specific clinical popu-
lations (eg, stroke39), languages (Thai40) had relatively 
small numbers41 or validated assessments against clin-
ical assessment rather than research reference standard 
assessment.42 Therefore, a formal, large validation study 
is necessary to provide definitive evidence of the diag-
nostic accuracy of the 4AT.
Comparison with the CAM is also of value, because 
the CAM is in use in some clinical units and thus infor-
mation on how the 4AT performs in relation to the 
CAM will help clinicians decide which tool is suitable 
for their particular context. Further information on 
how the 4AT performs as a cognitive screening tool, 
its ability to predict outcomes and how each item of 
the 4AT contributes to its diagnostic accuracy will also 
provide important guidance to clinicians. Finally, under-
standing the economic costs and benefits of using the 
4AT and the CAM will help providers in service pathway 
decisions.
Study objectives
The primary objective of the study is to determine the diag-
nostic accuracy of the 4AT for delirium detection versus 
the reference standard of a DSM-IV diagnosis.
The secondary objectives are:
a. to compare performance of the 4AT and the CAM;
b. to determine if the 4AT is an adequately sensitive 
tool for detecting general cognitive impairment as 
judged against a documented history of dementia 
and/or the Informant Questionnaire for Cognitive 
Decline in the Elderly (IQCODE);
c. to determine if 4AT scores predict important out-
comes such as length of stay, institutionalisation and 
mortality up to 12 weeks;
d. to determine the performance of individual items of 
the 4AT, for example, how accurate is altered level of 
alertness alone as a predictor of delirium diagnosis?
e. to assess the 4AT total score as a measure of delirium 
severity;
f. to estimate the delivery costs of the 4AT and CAM 
as a function of their diagnostic performance up to 
12 weeks as well as modelling longer term resource 
consequences.
METhodS And AnAlySIS
Study overview
Nine hundred patients aged 70 or over in EDs or acute 
general medical wards will be recruited in three sites 
(Edinburgh, Bradford and Sheffield). Study recruit-
ment commenced on 19 October 2015. Recruitment 
was planned to be completed in December 2016, with 
final follow-up data collection and locking of the data-
base in March 2017. The assessments are: (a) a refer-
ence standard delirium assessment lasting up to 20 min 
and (b) either the 4AT or the CAM lasting up to 10 min. 
The reference standard and 4AT or CAM assessments 
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will take place within a maximum of 2 hours of each 
other, with a target interval of 15 min. The results of 
the reference standard assessment were recorded in 
the case notes and communicated to the clinical team 
after the index assessments had been completed and 
recorded. The team will invite an appropriate informant 
to complete a questionnaire on participant’s preadmis-
sion cognitive function. This will be completed within 
4 weeks of the patient being recruited to the study 
assuming an appropriate individual is available.
At 12 weeks, the team will also administer a 10 min 
resource-use questionnaire (face to face in hospitalised 
patients or by telephone when possible) and will access 
each recruited patient's medical records at 12 weeks to 
ascertain a set of key clinical outcomes, including length 
of stay, institutionalisation and mortality, as well as to 
derive further information on resource utilisation. The 
study flow chart is shown in figure 1. The study has been 
registered: international standard randomised controlled 
trial number (ISRCTN) 53388093. UK Clinical Research 
Network ID: 19 502.
Inclusion criteria
 Ź Aged 70 or over.
Figure 1 Study overview low chart. CAM, Confusion Assessment Method; ED, emergency department; MOE, Medicine of the 
Elderly; 4AT, 4A's Test. 
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 Ź Acutely admitted to the ED (within 12 hours of 
attending) or acute general medical and geriatrics 
units (within 96 hours of admission to the ward). For 
ED patients, we will only recruit from those patients 
who were brought in by ambulance as an emergency 
or through their general practitioner.
Exclusion criteria
 Ź Acute life-threatening illness requiring time-crit-
ical intervention, for example, ST-elevation myocar-
dial infarction, septic shock and severe pulmonary 
oedema.
 Ź Coma (‘Unresponsive’ on the AVPU scale43).
 Ź Unable to communicate in English or severe dysphasia.
Identiication of participants
The participant screening strategy in the initial protocol 
stated that patients will be recruited between 08.00 and 
22.00. A list of potentially eligible patients will be gener-
ated in batches at the start of each recruitment period 
and initial eligibility screening will be carried out by clin-
ical staff (including clinical research nurses embedded 
in the clinical team). Then, in alphabetical order, in 
each batch, consent/agreement from patient (or proxy/
consultee) will be sought by a study researcher. Numbers 
of those (a) initially potentially eligible, (b) screened as 
non-eligible by clinical staff and (c) declining to take part 
will be recorded.
This recruitment strategy was modified in the last 5 
months of recruitment because preliminary analyses 
suggested that patients at lower risk of delirium (ie, those 
not requiring capacity assessment) were more likely to 
be recruited than those with impaired capacity. Thus, to 
allow for some oversampling of patients at higher risk of 
delirium, a pragmatic approach was adopted. From the 
batches of patients identified as in the original strategy, 
patients considered at higher risk of delirium on clin-
ical grounds (eg, older age, likely to be admitted, higher 
degree of ongoing acute and chronic illnesses) were 
approached first, rather than by alphabetical order.
Assessing capacity and obtaining informed consent
Informed consent will be sought by a trained researcher 
using a combined informal capacity assessment/consent 
process.44 Both verbal and written information will be 
provided about the study, using a style and format suit-
able for the participant group (ie, for varying levels of 
capacity). The researcher will ask the potential participant 
to recount the study which will be used, with the treating 
team views, to assess capacity to consent. For participants 
judged to have capacity, consent will be sought for:
a. conducting assessments as specified in the study in-
formation sheets;
b. accessing health records for information relevant to 
outcomes and health service use and
c. recording these data in secure study databases.
It will be made clear to participants that they are under 
no obligation to take part, their usual care will not be 
affected by their decision and they can withdraw consent 
without giving a reason. Once participants are enrolled in 
the study, they will be given a sheet with contact details for 
the research team and instructions on what to do if they 
wish to withdraw consent or require further information.
lack of capacity to consent
It is essential that this study recruits patients which reflect 
the target clinical population. This means that we must 
recruit patients with delirium in the same proportion as in 
the clinical population. We will seek consent/agreement 
from legal proxies, consultees or other legal representa-
tives. Where the potential participant is deemed to lack 
capacity to consent, recruitment will proceed under the 
provisions of the Mental Capacity Act, 2005 in England 
or Adults with Incapacity (Scotland) Act, 2000. The clin-
ical team will be asked to identify an appropriate personal 
or nominated consultee, guardian, welfare attorney or 
nearest relative.
Because of differing legal requirements in Scotland 
and England, the details of the processes in each nation 
are given in online Supplementary appendix 1.
Interventions to be measured
Assessments will be carried out by researchers fully trained 
in background information on delirium, the features of 
delirium and each rating scale. Training is carried out 
using written, video and bedside training until compe-
tence in all aspects of the assessments is achieved.
The 4 A’s Test
The 4AT (see www. the4AT. com) comprises four items. 
Item 1 concerns an observational assessment of level of 
alertness. The next two items are brief cognitive tests: 
the Abbreviated Mental Test–4 (AMT4) which asks the 
patient to state their age, their date of birth, the current 
year and the place they are in, and attention testing 
with Months Backwards, in which the patient is asked to 
state the months of year in reverse order, starting with 
December. Only items 1–3 are done at the bedside, and 
the typical duration is under 2 min. Item 4 concerns 
acute change in mental status, a core diagnostic feature 
of delirium; this information is obtained from the case 
notes or the general practitioner (GP) letter or from an 
informant.
Short CAM
The CAM is a diagnostic algorithm in which the tester 
rates the following four features as positive or negative: 
(1) Acute Change and Fluctuating Course; (2) Inatten-
tion; (3) Disorganised Thinking and (4) Altered Level of 
Consciousness. The CAM scoring process requires that 
Features 1 and 2 are both positive; if they are positive, 
then Features 3 and 4 are assessed and if one of Features 3 
or 4 is positive, then the whole CAM is positive. The tester 
scores the features by a combination of interview with the 
patient, cognitive testing (the CAM requires that a cogni-
tive test is performed before the features are scored), 
examining the case notes and seeking informant history 
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if required. Note that the questionnaires used to assess 
cognition are not specified by the CAM manual, though 
some suggested tests are provided. Feature 1 is assessed 
by the same process as Item 4 in the 4AT. Feature 2 is 
assessed by the tester giving a positive or negative rating 
to the question, ‘Did the patient have difficulty focusing 
attention, for example, being easily distractible or having 
difficulty keeping track of what was being said?’ Feature 3 
is assessed by the tester giving a positive or negative rating 
to the question, ‘Was the patient’s thinking disorganised 
or incoherent, such as rambling or irrelevant conversa-
tion, unclear or illogical flow of ideas or unpredictable 
switching from subject to subject?’ Feature 4 is similar to 
Item 1 in the 4AT. In this study, for the pre-CAM cogni-
tive assessment, we will use a set of questions covering the 
cognitive domains represented in the suggested tests in 
the CAM manual, including Days of the Week Backwards, 
counting from 20 down to 1, orientation questions, three-
word recall and clockdrawing, as well as simple orienta-
tion questions. All of these questions are used in routine 
clinical practice at the bedside.
Reference standard assessment
Reference standard assessment: this will be centred 
on the Delirium Rating Scale-Revised-98 (DRS-R98),45 
requiring inspection of case notes, speaking to staff who 
know the patient or speaking to the patient’s relatives or 
others who know them (with patient consent). As per the 
instruction manual, the DRS-R98 will be supplemented 
by short neuropsychological tests of attention and other 
domains, including Digit Span,27 the Observational Scale 
for Level of Arousal,46 the Richmond Agitation Seda-
tion Scale47 and the DelApp objective attentional assess-
ment.48 We will also perform simple orientation questions 
and record any formal prior diagnosis of dementia and 
IQCODE49 scores. The DRS-R98 and supporting tests will 
be used to inform a binary ascertainment of delirium 
based on DSM-IV criteria. The final DSM-IV ascertain-
ment of delirium will be based on a standardised process 
with final verification by the chief investigator, blind to 
the 4AT or CAM results. The panel of supporting tests, 
and the way the data are coded will be designed such that 
the performance of the 4AT can also be evaluated against 
the DSM-5 criteria.2 The reference standard assessment 
will take approximately 15–20 min.
ordering of assessments
All patients will undergo a reference standard assess-
ment for delirium by the researcher who conducted the 
capacity assessment and consenting process. A different 
researcher will also ask each patient to undergo either the 
4AT or the CAM. The reason that the researcher doing 
the capacity assessment and consenting process must also 
do the reference standard assessment is that the capacity 
and consenting process provides information to the tester 
over and above the normal 4AT or CAM testing process. 
This is not a concern for the reference standard assess-
ment, which is aimed at providing a thorough assessment 
so as to optimise diagnostic accuracy. The order of these 
two assessments ((4AT or CAM assessment) and reference 
standard assessment) will be randomly allocated immedi-
ately after consenting, as will the assignment to either the 
4AT or the CAM. Each patient will receive the reference 
standard assessment by the same researcher who did the 
capacity and consenting process. The 4AT or CAM will 
be performed by a different researcher. When possible, 
the IQCODE will then be administered to a person who 
knows the patient well (within 4 weeks of the patient 
joining the study).
Randomisation procedure
The allocation sequence will be created using comput-
er-generated random numbers. Participants will be 
randomised in a 1:1 ratio to be assessed using the 4AT 
or CAM experimental assessment. The order in which 
they receive the reference standard and experimental 
assessment will also be randomised in a 1:1 ratio. Rando-
misation will be stratified by study site with block alloca-
tion. The randomised allocations will be concealed until 
they are assigned, as the randomisation system will be 
web based and requires a personal login and password. 
Once randomisation has been performed, neither the 
researchers nor the participant will be blinded to the allo-
cation as both will be aware of the assessments conducted 
and the order in which they are performed.
outcome measurements (what, when, how)
Note that the outcome measurements for the primary 
study (the reference standard) are performed at almost 
the same time as the 4AT and CAM. The only subsequent 
data collection is capturing clinical outcomes at 12 weeks. 
This will be achieved through searching electronic 
patient records, telephone calls with participants or face-
to-face interviews if still in hospital. The information 
gleaned at the 12-week point will at times be generalised 
due to participant recall or availability of full electronic 
records.
(1) Primary outcome measure:
Diagnostic accuracy of the 4AT versus the reference 
standard delirium diagnosis
1. Secondary outcome measures:
2. 4AT versus CAM in relation to reference standard de-
lirium diagnosis.
3. Performance of 4AT cognitive test items (AMT4 and 
Months Backwards) in detecting longer term cogni-
tive impairment as detected by the IQCODE.
4. 4AT total scores as a predictor of the following clin-
ical outcomes as determined at 12 weeks post-test: 
length of stay, falls, institutionalisation (as assessed 
by proportion of patients newly admitted to care 
homes or awaiting care homes at that time) and 
mortality.
5. Performance of individual items of the 4AT in rela-
tion to reference standard delirium diagnosis.
6. We will assess the 4AT total score as a measure of de-
lirium severity.
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7. The primary output from the health economic anal-
ysis will be a comparison of the service delivery costs 
associated with the diagnostic accuracy of alternative 
(4AT vs CAM vs reference standard) triage tools for 
delirium.
Coding and recording assessments
The experimental assessments of delirium will be the 
4AT and the CAM. The 4AT has a total possible score of 
12: items (1) and (4) can score 0 or 4 and items (2) and 
(3) can score 0, 1 or 2.12 4AT data will be used for the 
primary objective as a binary outcome, with 0–3 scores 
giving a ‘no delirium’ classification, and 4–12 scores 
giving a ‘delirium’ classification; for the secondary objec-
tives, continuous scoring, from 0 to 12, will be studied 
as a possible severity indicator, and scores of 1–3 (indi-
cating cognitive impairment but not delirium) can be 
studied against other assessments of chronic cognitive 
impairment. The CAM will be scored as delirium present 
or absent according to the algorithm. The 4AT, CAM 
scoring and reference standard scoring will be recorded 
on a paper Case Report Form.
Patient resource use will be derived from medical 
records, including the ‘TrakCare’ (InterSystems Corpora-
tion, Cambridge, Massachusetts, USA) electronic patient 
record system, where available, as well as via patient or 
carer self-report. The self-report resource-use question-
naire will include questions regarding inpatient health 
and social care utilisation with a maximum recall period of 
16 weeks. The self-report resource-use questionnaire will 
be developed specifically for the study for use by patient 
or proxy respondent using guidance from the Database of 
Instruments for Resource Use Measurement.50 Adminis-
tration of the questionnaire will be conducted at 12 weeks 
by one of the researchers in the study team, face to face 
where patients are still hospitalised or via telephone. Data 
from the questionnaire will be recorded on a paper Case 
Report Form.
The data on all the Case Report Forms will be tran-
scribed into a secure database by the researchers or a 
suitably qualified member of the research team. This 
will be conducted using Edinburgh Clinical Trials Unit 
Standard Operating Procedures. Quality checking will be 
performed in 10% of Case Report Forms.
Sample size calculation
Four hundred and fifty patients will be randomised 
to assessment by 4AT and 450 to CAM. We will recruit 
sufficient patients to account for attrition, though we do 
not expect significant attrition because the recruitment, 
consenting and assessment process takes place over a 
small number of hours in a single episode. Of the 450 
patients within each assessment arm, 15% (67) would be 
expected to have delirium. The specificity of the triage 
tool would be estimated based on the 85% (383) without 
delirium, while the sensitivity would be estimated from 
the 67 with delirium. Based on the analysis using the 
normal approximation to the binomial distribution, the 
two-sided 95% CI widths for the specificity and sensitivity 
would be as shown in table 1 for a range of levels of diag-
nostic test performance.
It will therefore be possible to estimate the specificity 
precisely and the sensitivity with moderate precision. 
The precision in estimating negative predictive value 
would be expected to be similar to that for specificity; 
for positive predictive value, it would be expected to be 
similar to that for sensitivity. For the secondary objective 
of comparing 4AT and CAM, based on analysis by conti-
nuity corrected χ2 test, we have 83% power to detect a 
difference in specificity of 0.1, assuming a null hypothesis 
of specificity=0.70 for both tests and a two-sided 5% signif-
icance level. The corresponding difference detectable for 
sensitivity (null hypothesis sensitivity=0.7) would be 0.224 
with 80% power.
data analysis plan
The detailed statistical analysis plan (SAP) will be agreed 
prior to database lock and will be prepared by individuals 
blinded to the randomised allocations.
Primary objective
(a) 4AT versus reference standard: the diagnostic accu-
racy of 4AT versus the reference standard will be assessed 
using positive and negative predictive values, sensitivity 
and specificity. The exact binomial 95% CI will be reported 
for each measure. A ROC curve will be constructed to 
verify that the proposed cut point of greater than 3 on 
the 4AT score is appropriate. The area under the ROC 
curve and its 95% CI will be reported.
Secondary objectives
a. 4AT versus CAM: differences in each of sensitivity, 
specificity, positive and negative predictive values be-
tween 4AT and CAM will be tested by Fisher’s exact 
test and quantified by the difference in the two pro-
portions (4AT-CAM) and its 95% CI. To aid compar-
ison of 4AT and CAM, the overall performance of 
each will also be summarised using Youden’s Index 
(sensitivity minus false positive rate) and the OR of 
sensitivity to specificity.
b. Performance of the 4AT cognitive screening items: 
Is the 4AT an adequately sensitive tool for detect-
ing general cognitive impairment as judged against 
a documented history of dementia and/or the 
Table 1 Precision of speciicity, sensitivity estimation
Parameter
True level of 
parameter 95% CI width
Speciicity 0.5 ±0.050
Speciicity 0.7 ±0.046
Speciicity 0.9 ±0.030
Sensitivity 0.5 ±0.120
Sensitivity 0.7 ±0.110
Sensitivity 0.9 ±0.072
group.bmj.com on February 28, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
8 Shenkin SD, et al. BMJ Open 2018;8:e015572. doi:10.1136/bmjopen-2016-015572
Open Access 
IQCODE? This objective will be addressed using the 
same methods as for the primary objective.
c. 4AT versus clinical outcomes: as assessment of cri-
terion validity, we will assess the performance of 
the 4AT in predicting length of stay, institutional-
isation and mortality up to 12 weeks. Descriptive 
statistics of clinical outcomes will be presented for 
the groups with and without 4AT scores above the 
cut point of 3. The relationship between 4AT and 
each of mortality and institutionalisation will be 
analysed via logistic regression modelling; Kaplan-
Meier curves and the Cox proportional hazards 
model will be used to assess 4AT as a predictor of 
hospital length of stay. The logistic regression and 
Cox models will adjust for age, gender and pres-
ence of dementia.
d. Individual items: we will conduct analyses exam-
ining performance of individual items of the 4AT, 
for example, is altered level of alertness alone a good 
predictor of delirium diagnosis? (methods as per pri-
mary objective);
e. Delirium severity: we will assess the 4AT total score 
as a measure of delirium severity by calculating the 
Spearman correlation between 4AT and DRS-R98 
scores and its 95% CI.
Full details of the proposed statistical analyses for 
the primary objective and secondary objectives (a)–(e) 
will be documented in a SAP which will include details 
of methods for calculating derived variables, any sensi-
tivity and subgroup analyses and approaches to testing 
the assumptions in the statistical analyses. The SAP will 
outline the plan for validation of the statistical analysis.
Individuals with missing data for the reference diag-
nostic test will be removed from formal statistical analysis. 
Where any items of the CAM or 4AT were not able to be 
assessed, an overall delirium diagnosis will still be derived 
where possible based on the items which have been 
recorded. There will be no other imputation of missing 
delirium diagnoses.
(f) Delivery costs of the triage tools: we will estimate 
the delivery costs and subsequent resource consequences 
associated with the triage tools as a function of sensitivity 
and specificity from the perspective of the UK National 
Health Service (NHS). Potential resource consequences 
may include additional diagnostic procedures (eg, more 
detailed cognitive screening and brain imaging), altered 
management as well as readmissions. Healthcare resource 
use will be derived from medical records, including 
the ‘TrakCare’ (InterSystems Corporation, Cambridge, 
Massachusetts, USA) electronic patient record system, 
where available, as well as via patient or carer self-report. 
Monetary values will be attached to resource use, training 
and labour costs as well as the indirect costs of deliv-
ering each diagnostic tool using standard NHS pay and 
price estimates. Generalised linear models will be used 
to analyse 12 week cumulative costs which will inform 
longer term resource consequences within a decision 
analytic model.
Study oversight
Study oversight is through the trial steering committee, 
which will meet every 4 months during the study. The trial 
steering committee comprises two independent lay repre-
sentatives, three independent experts (one of whom is 
the Chair of the committee), the principal investigator 
(PI), the study statistician and representatives from the 
Edinburgh Clinical Trials Unit.
data protection
Data will be collected and handled in line with sponsor 
and Edinburgh Clinical Trials Unit Standard Operating 
Procedures and NHS Trust policies. All electronic data 
will be link anonymised.
dISCuSSIon
This study was designed to validate the 4AT against a 
reference standard assessment, as well as compare it with 
another commonly used test for assessment of delirium. 
Since the initial study design, the 4AT has been widely 
adopted nationally and internationally. The 4AT has been 
incorporated into routine practice in multiple interna-
tional centres, both in paper and electronic format, 
with many centres reporting 10 000 uses of the tool. The 
website www. the4AT. com has had an increasing degree 
of traffic, and the 4AT has been translated into multiple 
languages. The 4AT is also included in several national 
guidelines and position statements internationally as a 
recommended tool and it has been validated in other 
studies38–42 but it is still essential that it is further tested 
in a large study. It is also essential to consider how well it 
identifies other types of cognitive impairment, relates to 
future outcomes and its health economic impact.
In the initial design and implementation of the study, 
the main challenging aspects have been: (1) considering 
both Scottish and English legal and ethical framework to 
ensure that patients without capacity are included. Ethical 
approval for inclusion of these patients was granted 
though recruitment of this patient group proved diffi-
cult from the outset for several reasons. First, the narrow 
boundaries for the screening and identification strategy. 
This was addressed in a subsequent protocol amendment 
to aim for oversampling of patients at risk of developing 
delirium. Second, the availability of an appropriate 
individual to provide consent on behalf of the partici-
pant (ie, a personal or nominated consultee, guardian, 
welfare attorney or nearest relative). Third, a reluctance 
to consent due to perceived burden on participant. 
Persuading relatives of the value, importance and neces-
sity of research even in clinically unwell patients demands 
a particular skillset from researchers and involved perse-
verance and excellent communication in order to achieve 
recruitment targets.
(2) Recruitment and training of staff, with some staff 
moving to different posts, and new staff being recruited 
and requiring training; in each case, detailed training 
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supported by reading materials and practice sessions was 
provided.
We also acknowledge that it is possible that researcher 
bias may influence how the different index assessments 
(4AT or CAM) were scored. We also acknowledge that 
given the fluctuating nature of delirium, the gap between 
assessments potentially reaching 2 hours means that 
assessments could have different findings. We will conduct 
sensitivity analyses to analyse the impact of variations in 
the time gap between assessments.
ConCluSIon
The 4AT study aims to assess the validity of this rapid 
delirium screening tool that can be administered by a 
range of professional- level healthcare staff to patients 
with sensory or functional impairments in a busy clinical 
environment, which also incorporates general cogni-
tive assessment. We will also assess the later functional 
outcomes of people with and without delirium and the 
health economic implications. The overall aim is to 
improve detection, and therefore management and 
outcomes, of this important and devastating condition.
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